Today's News |
Fast Growing BC Biotherapeutics Company Zymeworks Files For Proposed IPO on New York Stock Exchange (and TSX)
Monday, April 10, 2017Company Profile | Follow Company
Vancouver, BC, April 10, 2017--(T-Net)--Zymeworks Inc., a Vancouver-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced that it has filed with the U.S. Securities and Exchange Commission (SEC) and the securities regulatory authorities in Canada for a proposed initial public offering (IPO) of its common shares.
The number of common shares to be sold and the price range for the proposed offering have not yet been determined.
Zymeworks has applied to list its common shares on the New York Stock Exchange and intends to apply to list its common shares on the Toronto Stock Exchange, under the ticker symbol “ZYME” for both exchanges.
Citigroup Global Markets Inc., Barclays Capital Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. Cannacord Genuity Inc. is acting as a lead manager. Cormark Securities (USA) Limited is acting as a co-manager.
-------------------------
Editor's Note: Zymeworks recently opened a state-of-the-art, 10,000 square foot laboratory facility in Vancouver, Canada back in February this year, and the company has been doing big deals with Eli Lilly and GlaxoSmithKline, and others.
A year ago (in Jan 2016), the company raised a massive CDN $86.6 Million (US$ 61.5 million) Series A mezzanine financing to support the advancement of its Azymetric™ therapeutics pipeline.
In July 2016, the company was honored as the Biotech Company of the Year by BIOTECanada.
More details to follow on this proposed IPO story.
-------------------------
Forward Looking Statements
This press release contains certain forward-looking statements, including statements with regard to Zymeworks' proposed initial public offering. Words such as “expects”, “anticipates” and “intends” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the initial public offering discussed above will be completed on the terms described. Completion of the proposed initial public offering and the terms thereof are subject to numerous factors, many of which are beyond Zymeworks' control, including, without limitation, failure of customary closing conditions and the risk factors and other matters set forth in Zymeworks' filings with the SEC and the securities commissions or similar securities regulatory authorities in each of the provinces and territories of Canada. Zymeworks undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Contact:
Investor Inquiries:
David Matousek
Senior Manager, Investor Relations & Corporate Communications
(604) 678-1388
ir@zymeworks.com
Stephanie Carrington
ICR Inc.
(646) 277-1282
stephanie.carrington@icrinc.com
Other Recent Company News |
||||||||||||||||||||
|